Has myelin basic protein received a fair trial in the treatment of multiple sclerosis?
Article first published online: 7 OCT 2004
Copyright © 1979 American Neurological Association
Annals of Neurology
Volume 6, Issue 6, pages 461–468, December 1979
How to Cite
Alvord, E. C., Shaw, C.-M., Hruby, S. and Kies, M. W. (1979), Has myelin basic protein received a fair trial in the treatment of multiple sclerosis?. Ann Neurol., 6: 461–468. doi: 10.1002/ana.410060602
- Issue published online: 7 OCT 2004
- Article first published online: 7 OCT 2004
- Manuscript Accepted: 7 MAY 1979
Autosensitization to some central nervous system antigen still remains one of the best hypotheses for the continuing pathogenesis of multiple sclerosis (MS). Enough is now known about the cause, pathogenesis, and treatment of experimental allergic encephalomyelitis (EAE) to test this hypotesis. Reports of therapeutic failure of the encephalitogen myelin basic protein (BP) in the treatment of MS have their counterparts in similar therapeutic failures in EAE. Only highly inbred strain 13 guinea pigs respond much less well to simple BP therapy, and monkeys hardly at all. In both strains of monkeys so far studied, a nonspecific adjunctive factor–an antibiotic in Macaca mulatta and a steroid in Macaca fascicularis—is also required. Accordingly, human trials of the therapeutic efficacy of BP in MS should include its administration in large concentrations together with an adjunctive agent.